A single arm, prospective Phase II study of Split-Course PelvicRadiotherapy for Locally Progressive, Castrate Resistant Prostate Cancer

Interventions: Split-course pelvic radiotherapy will consist of a dose of 55Gy in 22 fractions. This dose will be prescribed as a course of 25Gy in 10 fractions given over 2 weeks, followed by a planned 1 week treatment break, followed by a further 30Gy in 12 fractions given over 2 1/2 weeks.
Primary outcome(s): The primary objective of the trial is to test the hypothesis that split-course hypo-fractionated pelvic radiotherapy improves bladder health related quality of life in patients with local symptoms associated with castrate resistant prostate cancer (CRPC).
Outcome will be assessed using the EPIC Urinary Assessment[6 months];The co-primary objective of the trial is to test the hypothesis that split-course hypo-fractionated pelvic radiotherapy improves bowel health related quality of life in patients with local symptoms associated with castrate resistant prostate cancer (CRPC).
Outcome will be assessed using the EPIC Bowel Assessment[6 months]
Study Design: Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Efficacy